Contribute Try STAT+ Today

Amid mounting concerns over the U.S. pharmaceutical supply chain, a Department of Defense watchdog found an overreliance on foreign suppliers that could harm national security and that the Pentagon failed to assess the risks of shortages or develop strategies to mitigate disruptions.

Among the shortcomings, the Defense Department did not aggregate and analyze the origins of finished medicines or active ingredients to determine the reliance on foreign suppliers or identify gaps in information about where the products are made, according to the Office of Inspector General at DOD. The OIG report also noted the military is not required to run such analyses.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment